TrialLancet (London, England)2019

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.

Erik A Imel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.